Research Article
Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study
Table 2
Actionable biomarkers (i.e., biomarkers predictive of response to specific therapies) identified by immunohistochemistry and microarray analysis.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SPARC levels were considered high if either of the analyses (using monoclonal or polyclonal antibodies) demonstrated high SPARC expression levels. 5-FU: 5- fluorouracil; AR: androgen receptor; ASNS: asparagine synthetase; BRCA 1/2: breast cancer 1/2, early onset; EGFR: epidermal growth factor receptor; ER: estrogen receptor; ERCC1: excision repair cross complementation 1; FISH: fluorescent in situ hybridization; HER2: human epidermal growth factor receptor 2; HIF1A: hypoxia-inducible factor 1-alpha; IHC: immunohistochemistry; MGMT: O-6-methylguanine-DNA methyltransferase; PDGFR: platelet-derived growth factor receptor; PgR: progesterone receptor; RRM1: ribonucleotide reductase M1 subunit; RRM2B: ribonucleotide reductase M2 B; SPARC: secreted protein acidic, rich in cysteine; TLE3: transducin-like enhancer of split 3; TOP2B: topoisomerase II beta; TOPO1: topoisomerase 1; TOPO2A: topoisomerase IIA; TS: thymidylate synthase; VDR: vitamin D receptor. |